| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Dihydrostreptomycin Sulfate inhibits protein synthesis by binding to the 30S ribosomal subunit. This binding interferes with bacterial protein synthesis, leading to cell death. It is effective against most Gram-positive and Gram-negative bacteria.
|
|---|---|
| ln Vitro |
In vitro, dihydrostreptomycin sulfate is active against B. subtilis, K. pneumoniae, and S. marcescens. It inhibits protein synthesis by binding to the 30S ribosomal subunit. It is used to study aminoglycoside uptake.
|
| ln Vivo |
In vivo, dihydrostreptomycin sulfate is used to treat tuberculosis and tularemia. It is commonly used in veterinary medicine for treating infections in animals. It provides bactericidal activity against a range of bacterial pathogens.
|
| Enzyme Assay |
In vitro susceptibility testing for dihydrostreptomycin sulfate follows standard antimicrobial susceptibility testing guidelines. Broth microdilution or disk diffusion assays are performed using various bacterial strains. Minimum inhibitory concentrations (MICs) are determined. The compound's spectrum of activity is assessed.
|
| Cell Assay |
Cell-based assays for dihydrostreptomycin sulfate involve treating bacterial cultures with the compound and measuring bacterial growth inhibition. The compound's ability to inhibit protein synthesis is assessed by measuring incorporation of radiolabeled amino acids. Time-kill curves are performed to determine bactericidal activity.
|
| Animal Protocol |
In vivo animal studies for dihydrostreptomycin sulfate typically involve administration to animal models of bacterial infection. Efficacy is assessed by measuring bacterial load, survival, and clinical signs. Pharmacokinetic studies measure drug levels in plasma and tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of dihydrostreptomycin sulfate are characteristic of aminoglycoside antibiotics. The compound is poorly absorbed orally and is typically administered parenterally. It is distributed to extracellular fluids and excreted unchanged in the urine. The compound has a molecular weight of 1451.38 g/mol and a molecular formula of C40H86N14O37S3.
|
| Toxicity/Toxicokinetics |
Dihydrostreptomycin sulfate can cause nephrotoxicity and ototoxicity, similar to other aminoglycosides. It should be used with caution. The compound's safety profile requires careful monitoring, particularly in veterinary applications.
|
| Additional Infomation |
Dihydrostreptomycin Sulfate is a semi-synthetic aminoglycoside antibiotic with bactericidal activity. Dihydrostreptomycin Sulfate inhibits protein synthesis by binding to the 30S ribosomal subunit. This antibiotic is effective against most Gram-positive and Gram-negative bacteria and is used to treat tuberculosis and tularemia.
A semi-synthetic aminoglycoside antibiotic used to treat tuberculosis. See also: Dihydrostreptomycin Sulfate (active moiety); Dihydrostreptomycin Sulfate; Procaine penicillin G (component). Dihydrostreptomycin sulfate is a semi-synthetic aminoglycoside antibiotic used in veterinary medicine. It is a derivative of streptomycin. It is not approved for human therapeutic use in many countries due to toxicity concerns. The compound is a valuable tool for studying aminoglycoside antibiotics and bacterial protein synthesis. |
| Molecular Formula |
C42H88N14O36S3
|
|---|---|
| Molecular Weight |
1460.41
|
| CAS # |
5490-27-7
|
| PubChem CID |
21653
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
954.5ºC at 760 mmHg
|
| Flash Point |
531.1ºC
|
| Hydrogen Bond Donor Count |
32
|
| Hydrogen Bond Acceptor Count |
42
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
95
|
| Complexity |
993
|
| Defined Atom Stereocenter Count |
30
|
| SMILES |
S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].S(=O)(=O)(O[H])O[H].O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])/N=C(\N([H])[H])/N([H])[H])O[H])/N=C(\N([H])[H])/N([H])[H])O[H])O[H])[C@@]1([H])[C@@]([H])([C@@](C([H])([H])O[H])([C@]([H])(C([H])([H])[H])O1)O[H])O[C@@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])C([H])([H])[H].O([C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@]([H])([C@]1([H])/N=C(\N([H])[H])/N([H])[H])O[H])/N=C(\N([H])[H])/N([H])[H])O[H])O[H])[C@@]1([H])[C@@]([H])([C@@](C([H])([H])O[H])([C@]([H])(C([H])([H])[H])O1)O[H])O[C@@]1([H])[C@]([H])([C@@]([H])([C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])C([H])([H])[H]
|
| Synonyms |
AI3 50133; AI3-50133; Dihydrostreptomycin Sulfate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~342.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (136.85 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6847 mL | 3.4237 mL | 6.8474 mL | |
| 5 mM | 0.1369 mL | 0.6847 mL | 1.3695 mL | |
| 10 mM | 0.0685 mL | 0.3424 mL | 0.6847 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
